Drug adulteration analysis based on complexation with cyclodextrin and metal ions using ion mobility spectrometry / 药物分析学报

Drug adulteration and contamination are serious threats to human health therefore,their accurate monitoring is very important.Allopurinol(Alp)and theophylline(Thp)are commonly used drugs for the treatment of gout and bronchitis,while their isomers hypoxanthine(Hyt)and theobromine(Thm)have no effect and affect the efficacy of the drug.In this work,the drug isomers of Alp/Hyt and Thp/Thm are simply mixed with α-,β-,y-cyclodextrin(CD)and metal ions and separated using trapped ion mobility spectrometry-mass spectrometry(TIMS-MS).TIMS-MS results showed that Alp/Hyt and Thp/Thm iso-mers could interact with CD and metal ions and form corresponding binary or ternary complexes to achieve their TIMS separation.Different metal ions and CDs showed different separation effect for the isomers,among which Alp and Hyt could be successfully distinguished from the complexes of[Alp/Hyt+y-CD+Cu-H]+with separation resolution(Rp-p)of 1.51;whereas Thp and Thm could be baseline separated by[Thp/Thm+y-CD+Ca-H]+with Rp-p of 1.96.Besides,chemical calculations revealed that the complexes were in the inclusion forms,and microscopic interactions were somewhat different,making their mobility separation.Moreover,relative and absolute quantification was investigated with an internal standard to determine the precise isomers content,and good linearity(R2＞0.99)was ob-tained.Finally,the method was applied for the adulteration detection where different drugs and urine were analyzed.In addition,due to the advantages of fast speed,simple operation,high sensitivity,and no chromatographic separation required,the proposed method provides an effective strategy for the drug adulteration detection of isomers.

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Rheumatoid arthritis is a chronic, systemic autoimmune disease predominantly based on joint lesions with an extremely high disability and deformity rate. Several drugs have been used for the treatment of rheumatoid arthritis, but their use is limited by suboptimal bioavailability, serious adverse effects, and nonnegligible first-pass effects. In contrast, transdermal drug delivery systems (TDDSs) can avoid these drawbacks and improve patient compliance, making them a promising option for the treatment of rheumatoid arthritis (RA). Of course, TDDSs also face unique challenges, as the physiological barrier of the skin makes drug delivery somewhat limited. To overcome this barrier and maximize drug delivery efficiency, TDDSs have evolved in terms of the principle of transdermal facilitation and transdermal facilitation technology, and different generations of TDDSs have been derived, which have significantly improved transdermal efficiency and even achieved individualized controlled drug delivery. In this review, we summarize the different generations of transdermal drug delivery systems, the corresponding transdermal strategies, and their applications in the treatment of RA.

The relationship between serum thyroid hormone level and prognosis after cerebral infarction / 实用医学杂志

Objective To investigate the relationship between serum thyroid hormone level and prognosis after cerebral infarction.Methods Serum thyroid hormone level was determined in 88 patients with partial anteri-or circulation infarction(PACI)and large artery atherosclerotic(LAA)cerebral infarction.After 6-months rehabili-tation,the difference of serum thyroid hormone level was compared among all groups. Results Significant differ-ences of serum free triiodothyronine(FT3)were observed in patients with different prognosis(P < 0.01). Signifi-cant correlation was found between the low level FT3and the good prognosis(P < 0.01). Conclusions The de-crease of serum thyroid hormone level after cerebral infarction is protective,and the FT3level is negatively correlat-ed with the prognosis of patients with cerebral infarction.

ETME, a novel β-elemene derivative, synergizes with arsenic trioxide in inducing apoptosis and cell cycle arrest in hepatocarcinoma cells via a p53-dependent pathway

Arsenic trioxide (ATO) has been identified as an effective treatment for acute promyelocytic leukemia (APL) but is much less effective against solid tumors such as hepatocellular carcinoma (HCC). In the search for ways to enhance its therapeutic efficacy against solid tumors, we have examined its use in combination with a novel derivative of β-elemene, N-(β-elemene-13-yl)tryptophan methyl ester (ETME). Here we report the effects of the combination on cell viability, apoptosis, the cell cycle and mitochondria membrane potential (MMP) in HCC SMMC-7721 cells. We found that the two compounds acted synergistically to enhance antiproliferative activity and apoptosis. The combination also decreased the MMP, down-regulated Bcl-2 and pro-proteins of the caspase family, and up-regulated Bax and BID, all of which were reversed by the p53 inhibitor, pifithrin-α. In addition, the combination induced cell cycle arrest at the G2/M phase and reduced tumor volume and weight in an xenograft model of nude mice. Overall, the results suggest that ETME in combination with ATO may be useful in the treatment of HCC patients particularly those unresponsive to ATO alone.

Pneumonia in acute stroke patients / 中国实用内科杂志

Objective To study the risk factors of pneumonia in the acute stroke patients,and provide support for nursing. Methods 391 acute stroke patients were analysed to investigat the rate of pneumonia and its relation with age,the type and the severity of stroke, the basic disease and the prognosis. Results It was showed that the rate increased in the patients of old age, with severe stroke, and having some basic diseases such as diabetes, heart disease, tumor, immunity disease,old stroke. The mortality in the acute stroke patients with pneumonia was higher than the control. Conclusion Controlling the rate of pneumonia can help us to succeed in treating acute stroke patients.

Clinical study of target fibrinogen level treated by Batroxobin in patients with acute cerebral infarction / 临床神经病学杂志

130 mg/dl). Conclusions The fibrinogen level may reduce to 40～130 mg/dl treated with Batroxobin in patients with acute cerebral infarct, but whether it could be regarded as a target level need more studies.